MBRX, US60855L2034

Moleculin Biotech stock falls 32.71 percent on September 21

Published on 09/23/2026 at 01:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moleculin Biotech stock closed at USD 0.52 on September 21, 2026, down 32.71 percent. Market capitalization was USD 10.132 million.

MBRX, US60855L2034, Illustration mit AI erstellt.

Moleculin Biotech Inc. (ISIN US60855L2034) closed at USD 0.5202 on Nasdaq on September 21, 2026, down 32.71 percent from the prior close. The sharp move leaves the biotechnology stock with a market capitalization of USD 10.132 million, according to the latest market snapshot.

Stock move sets the peg

The September 21 decline is the clearest dated market signal for MBRX in the available trading data. At USD 0.5202, the stock sits in the micro-cap biotechnology segment, where a one-day move of 32.71 percent can materially change market value and trading liquidity.

Yahoo Finance identified Moleculin Biotech as MBRX and listed the September 21, 2026 quote at USD 0.5202, with market capitalization of USD 10.132 million and an industry classification of biotechnology.

Micro-cap valuation matters

The comparison between the closing price and the daily percentage change is material: a USD 0.5202 quote combined with a 32.71 percent session decline points to a highly compressed equity value. For investors, the market capitalization of USD 10.132 million on September 21, 2026 is the more useful scale measure than the share price alone.

The available market record also places Moleculin Biotech among the companies highlighted in a September 22, 2026 healthcare conference announcement. Business Insider listed Moleculin Biotech among the companies scheduled for the ROTH healthcare opportunities conference on September 29, 2026.

Nasdaq price remains the reference

The reference quotation is the Nasdaq close of USD 0.5202 on September 21, 2026. The same dated market signal records the 32.71 percent decline and the USD 10.132 million market capitalization, giving the stock a clearly defined price and valuation reference for September 2026.